During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...
March 4, 2011 (Boston, Massachusetts) — After years of concern that high-dose IV diuretics might compromise the kidneys and even survival compared with low-level dosing in acute decompensated heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback